VALIDATION OF PLASMA BIOMARKERS FOR PREDICTING AND PREVENTING ALCOHOL-ASSOCIATED RISK OF DEMENTIA: PRELIMINARY DATA

Background: Epidemiological research indicates that alcohol use disorder (AUD) is the most significant risk factor for early-onset dementia, potentially contributing to various types of dementia in individuals under 65 years old. Preliminary findings from our AUD study group suggest the presence of early fluidic biomarkers such as neurofilament light chain (Nfl) or Brain-derived neurotrophic factors (BDNF), which are associated with cognitive impairment. Furthermore, preclinical investigations in humanized mouse models have revealed an accelerated progression of Alzheimer's Disease (AD) neuropathology in conjunction with AUD.

Hypothesis and objectives: monitoring early fluidic markers associated with either AD or AUD (Nfl, BDNF, phosphorylated tau species, Aβ41/42, or phosphatidylethanol) could facilitate the implementation of early interventions aimed at preventing or mitigating dementia's progression.

Methods and Results: Throughout this presentation, we will present experimental and clinical evidence to discuss the diagnostic utility of these biomarkers as revealed from both plasma samples from biobanks associated with large cross-sectional studies, direct patient recruitment at primary care Addiction centers, and preclinical experimental data in animal models.  

Conclusions: There is a need to establish specific cohort studies for identifying dementia risk, both in AUD patients seeking treatment and in patients with subjective memory complaints. In addition, we will delve into a discussion on the necessity of addressing adolescent alcohol exposure as a risk factor for early-onset dementia, illuminated by preclinical studies demonstrating the impact of intensive binge drinking in adolescence on adult memory.